Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 1035-1038

  Cordery, Damien V ^a   Hesse, Karl ^b   Amin, Janaki ^a   Cooper, David A ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BILIRUBIN; CD4 ANTIGEN; RALTEGRAVIR; VIRUS RNA;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DEPRESSION; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; PYRROLIDINONES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; VIRAL LOAD;

EID: 78651068579     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1647     Document Type: Article

References (11)

1. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 2007; 369:1261-1269. (Pubitemid 46553846)
2. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 36:684-692.
3. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47:161-167.
4. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657-1663. (Pubitemid 47296061)
5. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33: 1729-1739.
6. Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis 2008; 47:137-140.
7. Zhu L, Mahnke L, Butterton J, et al. Pharmacokinetics and safety of twice daily atazanavir 300 mg and raltegravir 400 mg in healthy subjects. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 696.
8. Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants. J Int Assoc Physicians AIDS Care (Chic Ill) 2009; 8:87-92.
9. Ripamonti D, Maggiolo F, Bombana E, et al. Efficacy, safety and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral experienced patients. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract MOPEB067.
10. Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother 2005; 56:380-387. (Pubitemid 41158529)
11. Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008; 22:1890-1892.